Sildenafil Strami

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Sildenafil Strami

Property Description
Active ingredient Sildenafil (as Sildenafil citrate)
Form Oral tablet
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
Common use Circulatory modulator
Origin Synthetic, pyrazolo-pyrimidinone derivative

What Type of Medicine is Sildenafil Strami?

Sildenafil Strami is a specialized pharmaceutical preparation containing the active ingredient Sildenafil, classified as a Phosphodiesterase type 5 (PDE5) inhibitor. This medicinal entity is a prescription medicine and serves as a therapeutic agent within the class of enzyme inhibitors. Sildenafil is characterized by its specific selective action against the PDE5 enzyme.

The drug's unique identity is defined by its selective inhibitory action, which distinguishes it from non-specific vascular treatments. As a single-ingredient product, it is a synthetic compound, classified chemically as a pyrazolo-pyrimidinone derivative, a fact that guarantees a high degree of structural consistency required for predictable therapeutic use.


Sildenafil Strami: Composition, Form, and Origin

The composition is centered on the active ingredient Sildenafil (often formulated as Sildenafil citrate). The medication is typically manufactured as an oral tablet, the most common dosage form, which allows for simple and direct oral administration.

Sildenafil is an oral therapeutic agent supported by research for its use in conditions related to circulatory response. The tablet combines the measured dose of the Sildenafil substance with standard pharmaceutical excipients to create a solid matrix. Because Sildenafil is a synthetic chemical rather than one derived from natural sources, its high purity and consistent structure are key features in ensuring reliable therapeutic outcomes.


What is the General Purpose of Sildenafil Strami?

While specific conditions are detailed elsewhere, the general purpose of Sildenafil Strami is to improve localized blood flow by facilitating vasodilation through its highly targeted mechanism of effect. This action provides the necessary physiological support for the drug’s role as a circulatory modulator.

Sildenafil Strami achieves this by specifically inhibiting the PDE5 enzyme, which prevents the breakdown of a crucial chemical messenger called cyclic guanosine monophosphate (cGMP). The subsequent accumulation of cGMP signals smooth muscle relaxation and widening of artery walls. This targeted increase in blood flow is the key functional benefit, supporting the body's natural processes where blood supply is a necessary prerequisite.

Regulatory References

  1. European Medicines Agency
Advertisements

What side effects are possible with Sildenafil Strami?

Possible side effects and safety information

This information describes the documented safety profile and officially classified adverse reactions for Sildenafil Strami, based solely on regulatory authority documents.

Frequency-Classified Adverse Reactions

The following are the most frequently reported side effects:

  • Very Common (may affect more than 1 in 10 people):
    • Headache
  • Common (may affect up to 1 in 10 people):
    • Flushing
    • Dyspepsia (indigestion)
    • Abnormal vision (e.g., colour tinge, blurred vision)
    • Nasal congestion
    • Dizziness

Serious Adverse Reactions and Safety Restrictions

Serious Contraindications (Absolute Restrictions): Sildenafil Strami must not be used by anyone taking any form of organic nitrate or nitric oxide donors (e.g., nitroglycerin). This combination is strictly forbidden due to the risk of a severe, life-threatening drop in blood pressure. Use with guanylate cyclase stimulators is also contraindicated.

Serious Post-Marketing Events: Rare but serious events have been reported and require immediate medical attention. These include:

  • Sudden decrease or loss of vision (e.g., Non-Arteritic Anterior Ischemic Optic Neuropathy or NAION).
  • Sudden decrease or loss of hearing.
  • Priapism (an erection lasting longer than four hours).
  • Serious cardiovascular events, including myocardial infarction (heart attack) and stroke.

Population-Specific Safety Notes: Caution is advised for individuals with pre-existing severe cardiovascular conditions, recent heart attack or stroke (within six months), severe hepatic or renal impairment, or anatomical deformation of the penis (e.g., Peyronie's disease).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Sildenafil Strami is formally defined in regulatory documents as an exaggeration of known adverse effects occurring at increased doses. Clinical manifestations observed include increased rates and severities of adverse events, significant decreased blood pressure (hypotension), and syncope (fainting). In studies of single high doses, these manifestations were similar to lower-dose effects but more pronounced.

Regulatory guidance mandates immediate emergency action when specific time-critical or severe outcomes occur. Urgent medical attention is required for the following documented conditions:

Condition Required Action
Prolonged Erection (Priapism): If an erection persists longer than four hours. Seek immediate medical assistance to prevent permanent tissue damage and loss of potency.
Sudden Sensory Loss: Experiencing sudden loss of vision or sudden loss of hearing. Stop taking the medicine and seek immediate medical attention.

In the event of an overdose, regulatory prescribing information specifies that there is no specific antidote available. Management consists entirely of standard supportive measures and symptomatic treatment. Clearance procedures such as renal dialysis are not expected to accelerate the removal of Sildenafil due to its high plasma protein binding. Furthermore, official labeling notes that patients with severe hepatic or renal impairment may experience increased systemic exposure, a factor relevant to overdose risk.

Advertisements

Therapeutic Uses of Sildenafil Strami

What Sildenafil Strami Treats: Main Uses and Benefits

Sildenafil Strami is applied across domains where additional symptomatic support is considered relevant. The medication is relevant for managing symptoms that interfere with daily functioning across two therapeutic domains: Impaired Erectile Function in adult men and the symptoms of Pulmonary Arterial Hypertension (PAH) in adults and pediatric patients.

In the first domain, Sildenafil Strami may assist with the symptomatic manifestations of erectile dysfunction (ED), providing supportive relief when symptoms create noticeable physiological strain due to difficulty achieving adequate penile rigidity. In the cardiopulmonary domain, it helps to manage the symptoms of PAH, specifically shortness of breath and reduced exercise capacity.

This focus on targeted symptomatic support contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Relief for Functional Strain
Sildenafil Strami is used for managing symptoms that create noticeable physiological strain, supporting patients during episodes of heightened discomfort.
Advertisements

Eligibility and Restrictions for Use

Sildenafil Strami's eligibility for use is defined by specific criteria documented in official regulatory labeling, covering age, underlying health status, and co-medication status.

Populations and Conditions Prohibited or Contraindicated

Use is strictly contraindicated in patients with a known hypersensitivity to sildenafil or any component of the formulation. The medicine must not be used concurrently with organic nitrates or nitrites in any form, or with soluble guanylate cyclase (sGC) stimulators (e.g., riociguat).

Use is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD) or specific inherited degenerative retinal disorders like Retinitis Pigmentosa.

Established and Restricted Eligibility

Eligibility Category Regulatory Status
Established Use Adult men for ED and Adults and Pediatric patients (1–17 years) for PAH.
Caution Required Patients with severe hepatic or renal impairment, a history of NAION, recent Myocardial Infarction or Stroke (within 6 months), or conditions predisposing to Priapism.
Geriatric Patients Use requires caution due to potential reduced clearance.
Pregnancy/Lactation No adequate, controlled studies exist. Eligibility is determined based on the necessity of treating the mother’s underlying PAH.
Advertisements

What should I know about interactions with other medicines?

Sildenafil Strami carries important interaction constraints, primarily centered on the risk of severe blood pressure reduction and altered drug exposure.

Contraindicated Combinations

Sildenafil must never be used with nitrates or nitric oxide donors in any form (such as nitroglycerin, isosorbide mononitrate, or recreational alkyl nitrites like "poppers"). This combination can cause a life-threatening, dangerous drop in blood pressure. Use with soluble guanylate cyclase (sGC) stimulators, such as riociguat, is also strictly contraindicated for the same risk of profound hypotension.

Interactions Requiring Caution

  • Alpha-blockers and Antihypertensives: Co-administration with alpha-blockers or other blood pressure-lowering medicines may increase the risk of symptomatic hypotension due to additive vasodilatory effects. Therapy should be initiated only when the patient is stable on the alpha-blocker, typically starting Sildenafil at a lower dose.
  • CYP3A4 Modifiers: Sildenafil is metabolized mainly by the CYP3A4 liver enzyme. Potent CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, erythromycin) can increase Sildenafil blood levels and side effects, requiring a lower Sildenafil dose (e.g., a maximum of 25 mg over 48 hours with ritonavir). Conversely, CYP3A4 inducers (e.g., rifampin, bosentan) can reduce Sildenafil efficacy by lowering its plasma concentration.
  • Other PDE Type 5 Inhibitors: Sildenafil should not be used in combination with other products for erectile dysfunction or other PDE type 5 inhibitors (e.g., tadalafil, vardenafil).
Advertisements

Mechanism of Action

Selective Inhibition of the PDE5 Enzyme

Sildenafil is a selective inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which is responsible for the degradation of the signaling molecule cyclic Guanosine Monophosphate (cGMP). By binding reversibly to PDE5, the drug preserves cGMP levels within the target smooth muscle cells. This action is the core molecular step, amplifying the local physiological signal mediated by cGMP.


Amplification of the Nitric Oxide (NO)-cGMP Pathway

The drug's mechanism is contingent upon the natural physiological release of Nitric Oxide (NO), which triggers the synthesis of cGMP. Sildenafil then acts downstream to protect this cGMP, resulting in an accumulation of cGMP that mediates smooth muscle relaxation. This contingent action is essential because the mechanism is dependent on the prior release of Nitric Oxide (NO).


Modulation of Vascular Smooth Muscle Tone

The preservation of cGMP leads to the activation of downstream enzymes, causing a reduction in intracellular calcium ( Ca^2+) in the smooth muscle cells lining the arteries. This results in arterial vasodilation, a physiological change that decreases vascular resistance and facilitates regional blood inflow into the target tissues.

Advertisements

Dosage and Administration Information

How to Use Sildenafil Strami

Sildenafil is administered via the oral route as tablets or an oral suspension, with an intravenous (IV) bolus injection available for the Pulmonary Arterial Hypertension (PAH) indication. Its usage protocol is strictly determined by the therapeutic indication.

Usage Patterns by Indication

Indication Dosing Schedule Frequency & Timing
Impaired Erectile Function (IE) Starting dose: 50 mg; adjustable between 25 mg and a maximum of 100 mg. Used as needed, a maximum of once per day. Taken approximately one hour before activity (window: 30 minutes to 4 hours).
Pulmonary Arterial Hypertension (PAH) Standard oral dose: 20 mg; adjustable up to 80 mg. IV dose: 10 mg bolus. Used as a continuous, scheduled regimen three times a day (TID), with doses separated by 6 to 8 hours.

Administration Context and Adjustments

The oral tablet for IE may be taken with or without food; however, a high-fat meal can delay the rate of drug absorption. The oral suspension form for PAH must be shaken well for at least 10 seconds prior to measuring the dose.

Population-Specific Dose Initiation

A reduced starting dose of 25 mg for the IE indication is considered for specific populations, including older adults (ge 65 years) and patients with severe renal or hepatic impairment. When sildenafil is initiated while a patient is already stable on an alpha-blocker, the starting dose for IE is also limited to 25 mg.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Overview of Clinical Research

Research has examined whether the compound influences clinical outcomes in patients with the specified condition (X). Studies have investigated whether the compound is associated with changes in pain scores, which is a key symptom evaluated in clinical settings.

One study reported observations regarding a change in symptom severity over the trial period. The research investigated the compound's effect on cellular components to better understand its potential influence on bodily processes.


Studies on Administration and Use

Research evaluated administration of the compound, with the administration route being examined in relation to food intake. The specific combination of the compound was studied to see if it affects absorption rates in the body. Furthermore, the potential for interaction with specific substances was explored in controlled settings.

Research also examined whether the compound is associated with changes in markers of inflammation. Comparative research has compared the compound to other medications used for the condition. Studies were conducted under specific criteria, including that participants were included or excluded based on pre-existing conditions, such as heart conditions, to assess suitability across different populations.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sildenafil Strami (FAQ)


Q: How fast is Sildenafil Strami supposed to start working?

Sildenafil is absorbed quickly into the body after taking it orally. According to official product information, the highest level of the drug in the bloodstream is typically reached within 30 to 120 minutes, with a median time of about 60 minutes, when taken on an empty stomach.


Q: Does Sildenafil Strami last as long as other similar ED pills?

Regulatory data on how the body processes the drug indicate that the time it takes for the drug's concentration to decrease by half (its terminal half-life) is approximately 3 to 5 hours. This figure is used to describe the elimination rate from the body.


Q: What's the biggest difference between Sildenafil Strami and Viagra/Cialis?

Regulatory documents classify Sildenafil as a pyrazolo-pyrimidinone derivative, a type of PDE5 inhibitor. Official sources focus on its chemical structure and function but do not contain comparative statements about performance or specific duration against other similar products.


Q: Does alcohol make Sildenafil Strami less effective?

Sildenafil has properties that can lead to a drop in blood pressure due to its action as a vasodilator. Official product information notes that the co-consumption of alcohol may potentially enhance this blood pressure-lowering effect.


Q: How does age affect how well Sildenafil Strami works?

For the ED indication, older adults (age 65 years and older) may have higher plasma levels of the drug due to reduced clearance. Regulatory labeling advises considering a reduced starting dose for the ED indication in older adults due to the potential for reduced clearance.


Q: Can Sildenafil Strami cause a drop in blood pressure?

Yes, Sildenafil is a vasodilator, meaning it widens blood vessels. This action results in a mild and temporary decrease in blood pressure. This underlying vasodilatory action is the basis for the strict regulatory contraindication against using the drug with nitrates, which can cause a dangerous, additive drop in blood pressure.


Q: Can Sildenafil Strami cause stomach upset or nausea?

Official regulatory documents list indigestion (dyspepsia) as a common side effect of Sildenafil. Nausea is also included on some regulatory lists of adverse reactions that have been reported from clinical experience.


Q: Can Sildenafil Strami be used by women for any condition?

The Pulmonary Arterial Hypertension (PAH) indication is established for use in adults (both men and women) and pediatric patients. However, the indication for treating Erectile Dysfunction (ED) is specifically for adult men.


Q: How long after taking Sildenafil Strami is the concentration highest in your body?

When taken on an empty stomach, the maximum concentration of Sildenafil in the bloodstream is typically observed between 30 and 120 minutes after the dose. This peak concentration point is referred to in pharmacokinetics as T max.


Q: Can Sildenafil Strami interfere with anti-coagulant (blood thinner) medications?

Studies indicate that Sildenafil has no effect on bleeding time when taken alone or with aspirin. However, one PAH study reported a higher incidence of bleeding events, specifically nosebleeds, in patients who were concurrently receiving a Vitamin K antagonist.


Q: Does Sildenafil Strami work instantly, or do you need a certain level of arousal?

Sildenafil does not cause an automatic erection. For it to work for Erectile Dysfunction, the drug's action is dependent on the natural release of nitric oxide that occurs during sexual stimulation. Therefore, sexual stimulation is required for the drug to be effective.


Q: Why is there a warning about sudden hearing loss with Sildenafil Strami?

Official sources list sudden hearing loss as a rare, serious event reported after using PDE5 inhibitors. However, the available data does not establish a definitive causal link between the drug and this event.


Q: How is Sildenafil Strami different from similar PDE5 inhibitors at a chemical level?

Sildenafil is chemically classified as a pyrazolo-pyrimidinone derivative. Its mechanism shows selective inhibition of PDE5 over PDE3, an enzyme that is important for regulating heart muscle contraction.


Q: Are there specific food types that are better to avoid when taking Sildenafil Strami?

Official labeling states that taking the tablet with a high-fat meal may delay how quickly the drug is absorbed into the bloodstream. The drug's metabolism by the CYP3A4 enzyme is the basis for potential interactions with foods that are known to inhibit this enzyme.


Q: Does Sildenafil Strami interact with grapefruit or grapefruit juice?

Sildenafil is metabolized mainly by the CYP3A4 enzyme. Because grapefruit products are known inhibitors of CYP3A4, concurrent use may result in higher Sildenafil concentrations and a greater potential for side effects.


Q: What happens in the body when Sildenafil Strami is starting to wear off?

Sildenafil is primarily processed and eliminated from the body through the CYP3A4 enzyme in the liver. This metabolism breaks down Sildenafil into an active substance called the N-desmethyl metabolite, which is then further cleared from the body.


Q: Why do some people experience back pain after using Sildenafil Strami?

In clinical trials conducted for the treatment of Pulmonary Arterial Hypertension (PAH), back pain and muscle aches ( myalgia) were reported as adverse reactions. These effects are documented in official safety information for Sildenafil.


Q: Is Sildenafil Strami used in other countries under different names?

The active ingredient, Sildenafil, is widely used globally. Regulatory agencies acknowledge that the substance is available in various countries under multiple brand names, often as a generic equivalent of the reference medicine.


Q: Does Sildenafil Strami have any effect on sperm quality or fertility?

Regulatory documents refer to studies in healthy volunteers where no effect on sperm motility or morphology (shape) was observed.


Q: What kind of patient populations were included in the Sildenafil Strami research studies?

Research studies have included healthy volunteers in specific age ranges, as well as patients with the target conditions (ED or PAH). Studies are also often conducted in specific groups, such as those with varying degrees of kidney or liver impairment, to establish appropriate safety and clearance parameters.

Advertisements

How should Sildenafil Strami be stored and disposed of?

Storage and Handling Requirements

Sildenafil tablets must be stored at a controlled room temperature, specifically between 68°F and 77°F (20°C and 25°C), as defined by regulatory documents. The medication must be kept in its original container and protected from both excess moisture and light. Therefore, storage in damp areas like a bathroom is prohibited. The container must be kept tightly closed when not in use. A mandatory requirement is to always store Sildenafil out of the sight and reach of children.

Disposal Instructions

Unused or expired Sildenafil must be disposed of in accordance with local requirements. The product should not be thrown away in household trash or poured into wastewater unless local regulations explicitly permit it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sildenafil Strami found in:

A-Z Index: